These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 7858910)
21. Familial apolipoprotein AI and apolipoprotein CIII deficiency. Subclass distribution, composition, and morphology of lipoproteins in a disorder associated with premature atherosclerosis. Forte TM; Nichols AV; Krauss RM; Norum RA J Clin Invest; 1984 Nov; 74(5):1601-13. PubMed ID: 6501564 [TBL] [Abstract][Full Text] [Related]
22. New mouse models for lipoprotein metabolism and atherosclerosis. de Winther MP; Hofker MH Curr Opin Lipidol; 2002 Apr; 13(2):191-7. PubMed ID: 11891422 [TBL] [Abstract][Full Text] [Related]
23. Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol. Sakai T; Kamanna VS; Kashyap ML Arterioscler Thromb Vasc Biol; 2001 Nov; 21(11):1783-9. PubMed ID: 11701466 [TBL] [Abstract][Full Text] [Related]
24. Triacylglycerol-rich lipoproteins alter the secretion, and the cholesterol-effluxing function, of apolipoprotein E-containing lipoprotein particles from human (THP-1) macrophages. Lindholm EM; Palmer AM; Graham A Biochem J; 2001 Jun; 356(Pt 2):515-23. PubMed ID: 11368780 [TBL] [Abstract][Full Text] [Related]
26. Is reverse cholesterol transport a misnomer for suggesting its role in the prevention of atheroma formation? Quintão EC Atherosclerosis; 1995 Jul; 116(1):1-14. PubMed ID: 7488324 [TBL] [Abstract][Full Text] [Related]
27. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Skålén K; Gustafsson M; Rydberg EK; Hultén LM; Wiklund O; Innerarity TL; Borén J Nature; 2002 Jun; 417(6890):750-4. PubMed ID: 12066187 [TBL] [Abstract][Full Text] [Related]
28. Natural human apoA-I mutations L141RPisa and L159RFIN alter HDL structure and functionality and promote atherosclerosis development in mice. Tiniakou I; Kanaki Z; Georgopoulos S; Chroni A; Van Eck M; Fotakis P; Zannis VI; Kardassis D Atherosclerosis; 2015 Nov; 243(1):77-85. PubMed ID: 26363436 [TBL] [Abstract][Full Text] [Related]
29. Antioxidative and antiatherosclerotic effects of human apolipoprotein A-IV in apolipoprotein E-deficient mice. Ostos MA; Conconi M; Vergnes L; Baroukh N; Ribalta J; Girona J; Caillaud JM; Ochoa A; Zakin MM Arterioscler Thromb Vasc Biol; 2001 Jun; 21(6):1023-8. PubMed ID: 11397714 [TBL] [Abstract][Full Text] [Related]
30. [Separation of high density lipoproteins (HDL) using zonal ultracentrifugation in patients with apolipoprotein AI Milano variant]. Noseda G; Fragiacomo C; Cairoli R; Margon L; Franceschini G; Sirtori CR Schweiz Med Wochenschr; 1983 Dec; 113(50):1933-5. PubMed ID: 6420885 [TBL] [Abstract][Full Text] [Related]
31. Lipid markers for atherosclerosis. Kottke BA Am J Cardiol; 1986 Feb; 57(5):11C-17C. PubMed ID: 3080862 [TBL] [Abstract][Full Text] [Related]
32. Cholesterol efflux, lecithin-cholesterol acyltransferase activity, and pre-beta particle formation by serum from human apolipoprotein A-I and apolipoprotein A-I/apolipoprotein A-II transgenic mice consistent with the latter being less effective for reverse cholesterol transport. Castro G; Nihoul LP; Dengremont C; de Geitère C; Delfly B; Tailleux A; Fievet C; Duverger N; Denèfle P; Fruchart JC; Rubin EM Biochemistry; 1997 Feb; 36(8):2243-9. PubMed ID: 9047326 [TBL] [Abstract][Full Text] [Related]
33. Increased levels of high-density lipoprotein cholesterol are ineffective in inhibiting the development of immune responses to oxidized low-density lipoprotein and atherosclerosis in transgenic rabbits expressing human apolipoprotein (apo) A-I with severe hypercholesterolaemia. Boullier A; Hennuyer N; Tailleux A; Furman C; Duverger N; Caillaud JM; Castro G; Fievet C; Fruchart JC; Duriez P Clin Sci (Lond); 2001 Mar; 100(3):343-55. PubMed ID: 11222122 [TBL] [Abstract][Full Text] [Related]
34. CER-001, a HDL-mimetic, stimulates the reverse lipid transport and atherosclerosis regression in high cholesterol diet-fed LDL-receptor deficient mice. Tardy C; Goffinet M; Boubekeur N; Ackermann R; Sy G; Bluteau A; Cholez G; Keyserling C; Lalwani N; Paolini JF; Dasseux JL; Barbaras R; Baron R Atherosclerosis; 2014 Jan; 232(1):110-8. PubMed ID: 24401224 [TBL] [Abstract][Full Text] [Related]
35. Gene activation, apolipoprotein A-I/high density lipoprotein, atherosclerosis prevention and longevity. Luoma PV Pharmacol Toxicol; 1997 Aug; 81(2):57-64. PubMed ID: 9298501 [TBL] [Abstract][Full Text] [Related]
36. Pharmacology of apolipoprotein A-I. Andersson LO Curr Opin Lipidol; 1997 Aug; 8(4):225-8. PubMed ID: 9253539 [TBL] [Abstract][Full Text] [Related]
37. Defining the atherogenicity of large and small lipoproteins containing apolipoprotein B100. Véniant MM; Sullivan MA; Kim SK; Ambroziak P; Chu A; Wilson MD; Hellerstein MK; Rudel LL; Walzem RL; Young SG J Clin Invest; 2000 Dec; 106(12):1501-10. PubMed ID: 11120757 [TBL] [Abstract][Full Text] [Related]
39. Substitutions of glutamate 110 and 111 in the middle helix 4 of human apolipoprotein A-I (apoA-I) by alanine affect the structure and in vitro functions of apoA-I and induce severe hypertriglyceridemia in apoA-I-deficient mice. Chroni A; Kan HY; Kypreos KE; Gorshkova IN; Shkodrani A; Zannis VI Biochemistry; 2004 Aug; 43(32):10442-57. PubMed ID: 15301543 [TBL] [Abstract][Full Text] [Related]